CERUS (CERS) Company Report

Cerus reported record product revenue of $52.7 million for Q3 2025, marking a 15% year-over-year increase, and subsequently raised its full-year 2025 product revenue guidance to $202-$204 million. The company also achieved its sixth consecutive quarter of positive non-GAAP adjusted EBITDA, totaling $5 million for the quarter.
The IFC business saw significant growth, with product revenue increasing approximately 70% to $3.9 million and volume demand rising approximately 110% year-over-year in Q3 2025. Cerus is strategically shifting IFC sales from direct to hospitals to kit sales to blood centers, with approximately 70% of dose-equivalent unit sales tied to kits in Q3 2025, a move expected to streamline contracting and improve gross margins.
In pipeline and regulatory updates, Cerus completed enrollment of the last patient in the US phase 3 REDIS trial in October, with results anticipated in the second half of 2026. However, the CE mark decision for Intercept red blood cells in Europe is expected to be delayed by at least six months due to a transition in the competent authority review. The INT200 illumination device launch is progressing well in Europe, with a planned US PMA submission to the FDA in mid-2026.

Nov 6, 2025, 9:30 PM

Transcript

Cerus Announces Record Q3 2025 Results and Raises Full-Year Product Revenue Guidance

CERS

Earnings

Guidance Update

Revenue Acceleration/Inflection

Cerus Corporation reported record results for the third quarter ended September 30, 2025, with total revenue increasing 19% year-over-year to $60.2 million and product revenue rising 15% to $52.7 million.
For Q3 2025, the company achieved a GAAP net loss attributable to Cerus of $0.02 million and non-GAAP adjusted EBITDA of $5.0 million.
The company raised its full-year 2025 product revenue guidance to a range of $202 million to $204 million, reflecting 12% to 13% growth from 2024.
As of September 30, 2025, cash, cash equivalents, and short-term investments totaled $78.5 million.

Nov 6, 2025, 9:03 PM

8-K

Cerus Reports Strong Q2 Results and Provides Updates on Product Pipeline and Financial Outlook

CERS

Guidance Update

Revenue Acceleration/Inflection

Product Launch

Cerus reported strong Q2 results with 16% year-over-year growth and increased full-year guidance to a new range of $200 million to $203 million. The company anticipates being operating cash flow positive for the full year and expects to achieve its second consecutive year of positive adjusted EBITDA.
The Intercept FibroGen Complex (IFC) product guidance was increased to $16 million to $18 million, representing an almost doubling of its profile, and it targets a $300 million total addressable market with primary commercial focus in the United States.
The INTERCEPT platelet product has achieved 65-70% penetration in the US and is seeing new guidance documents in Germany that model the US situation, with significant global growth opportunities in Asia Pacific, China, Japan, and Latin America.
Cerus is progressing with its red blood cell product, with an expected European approval decision in H2 2026 and US clinical data also anticipated in H2 2026 to support a future PMA submission.
The company holds approximately $80 million in cash on its balance sheet and has $65 million in term debt that begins amortizing in April, with an option to extend for an additional year.

Sep 3, 2025, 4:04 PM

Ceribell Raises 2025 Revenue Forecast

CERS

Guidance Update

Earnings

Revenue Acceleration/Inflection

Ceribell Inc. has raised its revenue forecast for 2025 to between $85 million and $88 million, representing an anticipated growth of 30% to 34% over the previous year.
In the second quarter of 2025, the company reported revenue of $21.2 million, a 38% increase year-over-year, driven by strong commercial execution.
Despite robust revenue growth and a high gross margin of 88%, Ceribell continues to face profitability challenges with negative operating and net margins, and an EPS of -$1.33.
Operating expenses significantly increased in Q2 2025 to $33.6 million from $21.6 million in the prior year.
Notable insider selling activity includes five transactions totaling 113,633 shares sold over the past three months.

Aug 5, 2025, 8:46 PM

Morningstar

Cerus Corporation Announces Second Quarter 2025 Financial Results and Raises Full-Year Guidance

CERS

Earnings

Guidance Update

New Projects/Investments

Cerus Corporation reported second quarter 2025 total revenue of $60.1 million, with product revenue reaching a record $52.4 million, representing a 16% increase year-over-year.
The company raised its full-year 2025 product revenue guidance to a range of $200 million to $203 million, up from the previous range of $194 million to $200 million.
For the second quarter of 2025, net loss attributable to Cerus Corporation was $5.7 million, while non-GAAP adjusted EBITDA was positive $0.9 million, marking another quarter of positive non-GAAP adjusted EBITDA.
Growth was notably driven by increased customer demand for INTERCEPT Fibrinogen Complex (IFC), with Q2 IFC revenue at $5.6 million, and the company also received an additional $7.2 million in funding from the U.S. Department of Defense for lyophilized IFC development.

Aug 5, 2025, 8:01 PM

Press Release

Cerus Corp Highlights Global Innovation and Growth Initiatives in FY2025

CERS

Revenue Acceleration/Inflection

New Projects/Investments

Product Launch

Market leadership and mission: Cerus Corp emphasized its role as the global market leader in pathogen reduction technologies, dedicated to safeguarding the blood supply with a recurring revenue model and long-standing customer relationships.
Robust financial outlook: The company provided FY2025 revenue guidance of $194M–$200M and highlighted its continued positive non-GAAP EBITDA momentum, underpinning its strategy for sustained growth.
Advancing product innovation: Key updates were shared on the INTERCEPT Red Cells program, including promising Phase III (ReCePI study) outcomes for non-inferiority in anemia treatment, along with accelerated adoption of the INTERCEPT fibrinogen complex that enhances treatment turnaround in acute care settings.

Jun 11, 2025, 5:13 PM

Cerus Corp Q1 2025 Earnings Results & Financial Highlights

CERS

Earnings

Guidance Update

Product Launch

Revenue Acceleration/Inflection

Product revenue increased by 13% to $43.2M in Q1 2025, driving total revenue to $48.9M with $5.6M from government contracts. ,
Strong U.S. market performance with North American growth at 22% and U.S. IFC sales rising from $1.9M to $3.0M, driven by robust platelet kit demand.
Profitability turnaround achieved with net loss reduced to $7.7M (or $0.04 per share) and positive non-GAAP EBITDA of $0.2M. ,
Reiterated full-year product revenue guidance of $194M–$200M with expected IFC revenue of $12M–$15M and improved gross margins from 55.4% to 58.8%. ,,
Achieved an earlier-than-expected CE Mark for the next-generation LED-based INT-200 device, paving the way for global expansion and a U.S. launch following PMA submission in 2026. ,

May 1, 2025, 8:31 PM

Transcript 8-K

Earnings Transcripts

Quarterly earnings call transcripts for CERUS.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did William Greenman say about margins?What are CERUS's strategic priorities?How is CERUS positioned vs competitors?How did CERUS do last quarter?

Let Fintool AI Agent track CERUS's earnings for you

Get instant analysis when filings drop